Some patients treated with immunotherapy may develop lifelong endocrine conditions requiring ongoing hormone replacement, insulin therapy and long-term monitoring, according to Vi ...

A moving journey through breast cancer, discovering that vulnerability is courage and a diagnosis doesn't have to define your spirit or faith. A breast cancer survivor shares how faith and community ...

New research shows that lymphoma survivors often face long-term peripheral neuropathy, which may be more severe than what ...

Neoadjuvant Enhertu→THP improved pCR to 67.3% vs 56.3% with AC→THP in stage II–III high-risk HER2-positive disease (DESTINY-Breast11). Adjuvant Enhertu achieved 3-year IDFS 92.4% vs 83.7% with T-DM1 ...

FDA approved adjuvant atezolizumab for post-cystectomy MIBC with ctDNA MRD positivity, alongside Signatera CDx as the required companion diagnostic for eligibility determination. IMvigor011 randomized ...

A 15-patient, single-institution pilot longitudinally paired symptom surveys and stool profiling from baseline to 12 weeks after ICI initiation to explore microbiome–symptom associations. Fatigue ...

Melanoma patients preparing for inpatient TIL therapy learn what to pack, how chemo feels, and how IL‑2 side effects are managed. Close monitoring during interleukin-2 (IL-2) therapy is essential for ...

FDA accelerated approval covers relapsed/refractory MCL after ≥2 lines including a BTK inhibitor, positioning sonrotoclax as ...

Researchers at Moffitt Cancer Center are studying DYV800, a topical cream designed to reduce tumor acidity and help the ...

Indications span MF and PV in adults, plus acute/chronic GVHD in patients ≥12 years, positioning XR as a once-daily ...

SEER 1975–2023 analysis demonstrated a long-term mortality inflection from rising rates to sustained declines, with the ...

This segment focuses on how patients with advanced melanoma typically respond when introduced to subcutaneous immunotherapy ...